NCT01089101 2026-03-18
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
AstraZeneca
Children's National Research Institute
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Therapeutic Advances in Childhood Leukemia Consortium